13D Filing: SC Fundamental Value Fund, L.P. and Aviragen Therapeutics Inc. (AVIR)

Page 1 of 12

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
SC Fundamental Value Fund 0 1,830,643 0 1,830,643 1,830,643 4.74%
SC Fundamental 0 1,830,643 0 1,830,643 1,830,643 4.74%
Peter M. Collery 0 1,868,143 0 1,868,143 1,868,143 4.83%
Neil H. Koffler 0 1,830,643 0 1,830,643 1,830,643 4.74%
John T. Bird 0 1,830,643 0 1,830,643 1,830,643 4.74%
David A. Hurwitz 0 1,830,643 0 1,830,643 1,830,643 4.74%
SC Fund Management Profit Sharing Plan 0 37,500 0 37,500 37,500 0.10%

Page 1 of 12 – SEC Filing


DC 20549


No. 2)


to be included in statements filed pursuant

to rules 13d-1(a) and amendments thereto

pursuant to rule 13d-2(a)1

Therapeutics, Inc.

of Issuer)

Stock, par value $0.10 per share

of Class of Securities)



H. Koffler c/o SC Fundamental LLC

Third Avenue, 27th Floor

York, New York 10017

Address and Telephone Number of Person Authorized to Receive Notice and Communications)

16, 2018

of Event Which Requires Filing of this Statement)

the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. o


Note: Schedules
filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be sent.


1            The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.


information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes). 

Follow Vaxart Inc. (NASDAQ:VXRT)

Page 1 of 12